DUXAP9 and metastatic malignant neoplasm in the lymph nodes: A high level of DUXAP9 is positively associated with lymph node metastasis, poor pathological differentiation, advanced clinical stage, worse overall survival, and worse disease‐specific survival in OSCC patients.